|
gptkbp:instanceOf
|
gptkb:drug
eugeroic
|
|
gptkbp:approvalYear
|
1998 (US)
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:N06BA07
|
|
gptkbp:bioavailability
|
80-90%
|
|
gptkbp:brand
|
gptkb:Provigil
|
|
gptkbp:CASNumber
|
gptkb:68693-11-8
|
|
gptkbp:category
|
gptkb:drug
stimulant
nootropic
wakefulness-promoting agent
|
|
gptkbp:chemicalClass
|
benzhydryl sulfinyl compound
|
|
gptkbp:contraindication
|
hypersensitivity to modafinil
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Lafon_Laboratories
|
|
gptkbp:discoveredBy
|
gptkb:Michel_Jouvet
|
|
gptkbp:eliminationHalfLife
|
12-15 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1970s
|
|
gptkbp:hasMolecularFormula
|
gptkb:C15H15NO2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
modafinil
|
|
gptkbp:IUPACName
|
gptkb:2-[(diphenylmethyl)sulfinyl]acetamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine reuptake inhibitor
histamine release
orexin activation
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:offLabelUse
|
gptkb:depression
ADHD
cognitive enhancement
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
60%
|
|
gptkbp:PubChem_CID
|
gptkb:DB00745
CHEMBL651
4236
|
|
gptkbp:riskOfDependence
|
low
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
nervousness
insomnia
|
|
gptkbp:synonym
|
gptkb:2-[(diphenylmethyl)sulfinyl]acetamide
|
|
gptkbp:UNII
|
R3T0OMM39T
|
|
gptkbp:usedFor
|
gptkb:shift_work_sleep_disorder
narcolepsy
obstructive sleep apnea
|
|
gptkbp:bfsParent
|
gptkb:BALCO_scandal
gptkb:dopamine_transporter
gptkb:Shift_work_sleep_disorder
gptkb:@gwern
|
|
gptkbp:bfsLayer
|
7
|